APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Advanced Biopharmaceutical Therapies

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Advanced Biopharmaceutical Therapies Market Outlook and Growth Opportunities 2026

Report ID 174052720415 April 2026Not stated

Choose your research edition.

Industry ResearchAdvanced Biopharmaceutical Therapies Industry Research Report 2026126 pages · $2,950 USDIndustry Growth & TrendsGlobal Advanced Biopharmaceutical Therapies Industry Growth and Trends Forecast to 2032111 pages · $3,450 USDMarket StructureGlobal Advanced Biopharmaceutical Therapies Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Advanced Biopharmaceutical Therapies Market Outlook and Growth Opportunities 2026$4,250 USDMarket Analysis & ForecastGlobal Advanced Biopharmaceutical Therapies Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Advanced Biopharmaceutical Therapies market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Advanced Biopharmaceutical Therapies is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Advanced Biopharmaceutical Therapies is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Advanced Biopharmaceutical Therapies is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Advanced Biopharmaceutical Therapies market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Advanced Biopharmaceutical Therapies market include Lonza, Thermo Fisher Scientific, Catalent, Samsung Biologics, AGC Biologics, WuXi AppTec, Charles River Laboratories, Cytiva and Rentschler Biopharma, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Advanced Biopharmaceutical Therapies market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Advanced Biopharmaceutical Therapies and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Advanced Biopharmaceutical Therapies revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Advanced Biopharmaceutical Therapies market.

Advanced Biopharmaceutical Therapies Segment by Company

Lonza

Thermo Fisher Scientific

Catalent

Samsung Biologics

AGC Biologics

WuXi AppTec

Charles River Laboratories

Cytiva

Rentschler Biopharma

Oxford Biomedica

OmniaBio

Genezen

Cellipont Bioservices

VectorBuilder

Viralgen

ABL Europe

Advanced Biopharmaceutical Therapies Segment by Type

Cell Therapy Services

Gene Therapy Services

Nucleic Acid Therapy Services

Advanced Biopharmaceutical Therapies Segment by Application

Biopharmaceutical Industry

Research and Education Institutions

Others

Advanced Biopharmaceutical Therapies Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Advanced Biopharmaceutical Therapies status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Advanced Biopharmaceutical Therapies key companies, revenue, market share, and recent developments.

3. To split the Advanced Biopharmaceutical Therapies breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Advanced Biopharmaceutical Therapies market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Advanced Biopharmaceutical Therapies significant trends, drivers, influence factors in global and regions.

6. To analyze Advanced Biopharmaceutical Therapies competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Advanced Biopharmaceutical Therapies market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Advanced Biopharmaceutical Therapies and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Advanced Biopharmaceutical Therapies.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Advanced Biopharmaceutical Therapies industry.

Chapter 3: Detailed analysis of Advanced Biopharmaceutical Therapies company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Advanced Biopharmaceutical Therapies in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Advanced Biopharmaceutical Therapies in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Advanced Biopharmaceutical Therapies Industry Trends Table 2. Advanced Biopharmaceutical Therapies Industry Drivers Table 3. Advanced Biopharmaceutical Therapies Industry Opportunities and Challenges Table 4. Advanced Biopharmaceutical Therapies Industry Restraints Table 5. Global Advanced Biopharmaceutical Therapies Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Advanced Biopharmaceutical Therapies Revenue Share by Company (2021-2026) Table 7. Global Advanced Biopharmaceutical Therapies Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Advanced Biopharmaceutical Therapies Key Company Manufacturing Base & Headquarters Table 9. Global Advanced Biopharmaceutical Therapies Company, Product Type & Application Table 10. Global Advanced Biopharmaceutical Therapies Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Advanced Biopharmaceutical Therapies by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Cell Therapy Services Table 15. Significant Companies of Gene Therapy Services Table 16. Significant Companies of Nucleic Acid Therapy Services Table 17. Global Advanced Biopharmaceutical Therapies Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Advanced Biopharmaceutical Therapies Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Advanced Biopharmaceutical Therapies Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Advanced Biopharmaceutical Therapies Sales Value Share by Type (2021-2026) Table 21. Global Advanced Biopharmaceutical Therapies Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Biopharmaceutical Industry Table 23. Significant Companies of Research and Education Institutions Table 24. Significant Companies of Others Table 25. Global Advanced Biopharmaceutical Therapies Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Advanced Biopharmaceutical Therapies Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Advanced Biopharmaceutical Therapies Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Advanced Biopharmaceutical Therapies Sales Value Share by Application (2021-2026) Table 29. Global Advanced Biopharmaceutical Therapies Sales Value Share by Application (2027-2032) Table 30. Global Advanced Biopharmaceutical Therapies Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Advanced Biopharmaceutical Therapies Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Advanced Biopharmaceutical Therapies Sales Value Share by Region (2021-2026) Table 33. Global Advanced Biopharmaceutical Therapies Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Advanced Biopharmaceutical Therapies Sales Value Share by Region (2027-2032) Table 35. Global Advanced Biopharmaceutical Therapies Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Advanced Biopharmaceutical Therapies Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Advanced Biopharmaceutical Therapies Sales Value Market Share by Country (2021-2026) Table 38. Global Advanced Biopharmaceutical Therapies Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Advanced Biopharmaceutical Therapies Sales Value Market Share by Country (2027-2032) Table 40. Lonza Company Information Table 41. Lonza Business Overview Table 42. Lonza Advanced Biopharmaceutical Therapies Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Lonza Advanced Biopharmaceutical Therapies Product Portfolio Table 44. Lonza Recent Development Table 45. Thermo Fisher Scientific Company Information Table 46. Thermo Fisher Scientific Business Overview Table 47. Thermo Fisher Scientific Advanced Biopharmaceutical Therapies Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Thermo Fisher Scientific Advanced Biopharmaceutical Therapies Product Portfolio Table 49. Thermo Fisher Scientific Recent Development Table 50. Catalent Company Information Table 51. Catalent Business Overview Table 52. Catalent Advanced Biopharmaceutical Therapies Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Catalent Advanced Biopharmaceutical Therapies Product Portfolio Table 54. Catalent Recent Development Table 55. Samsung Biologics Company Information Table 56. Samsung Biologics Business Overview Table 57. Samsung Biologics Advanced Biopharmaceutical Therapies Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Samsung Biologics Advanced Biopharmaceutical Therapies Product Portfolio Table 59. Samsung Biologics Recent Development Table 60. AGC Biologics Company Information Table 61. AGC Biologics Business Overview Table 62. AGC Biologics Advanced Biopharmaceutical Therapies Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. AGC Biologics Advanced Biopharmaceutical Therapies Product Portfolio Table 64. AGC Biologics Recent Development Table 65. WuXi AppTec Company Information Table 66. WuXi AppTec Business Overview Table 67. WuXi AppTec Advanced Biopharmaceutical Therapies Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. WuXi AppTec Advanced Biopharmaceutical Therapies Product Portfolio Table 69. WuXi AppTec Recent Development Table 70. Charles River Laboratories Company Information Table 71. Charles River Laboratories Business Overview Table 72. Charles River Laboratories Advanced Biopharmaceutical Therapies Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Charles River Laboratories Advanced Biopharmaceutical Therapies Product Portfolio Table 74. Charles River Laboratories Recent Development Table 75. Cytiva Company Information Table 76. Cytiva Business Overview Table 77. Cytiva Advanced Biopharmaceutical Therapies Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Cytiva Advanced Biopharmaceutical Therapies Product Portfolio Table 79. Cytiva Recent Development Table 80. Rentschler Biopharma Company Information Table 81. Rentschler Biopharma Business Overview Table 82. Rentschler Biopharma Advanced Biopharmaceutical Therapies Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Rentschler Biopharma Advanced Biopharmaceutical Therapies Product Portfolio Table 84. Rentschler Biopharma Recent Development Table 85. Oxford Biomedica Company Information Table 86. Oxford Biomedica Business Overview Table 87. Oxford Biomedica Advanced Biopharmaceutical Therapies Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Oxford Biomedica Advanced Biopharmaceutical Therapies Product Portfolio Table 89. Oxford Biomedica Recent Development Table 90. OmniaBio Company Information Table 91. OmniaBio Business Overview Table 92. OmniaBio Advanced Biopharmaceutical Therapies Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 93. OmniaBio Advanced Biopharmaceutical Therapies Product Portfolio Table 94. OmniaBio Recent Development Table 95. Genezen Company Information Table 96. Genezen Business Overview Table 97. Genezen Advanced Biopharmaceutical Therapies Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 98. Genezen Advanced Biopharmaceutical Therapies Product Portfolio Table 99. Genezen Recent Development Table 100. Cellipont Bioservices Company Information Table 101. Cellipont Bioservices Business Overview Table 102. Cellipont Bioservices Advanced Biopharmaceutical Therapies Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 103. Cellipont Bioservices Advanced Biopharmaceutical Therapies Product Portfolio Table 104. Cellipont Bioservices Recent Development Table 105. VectorBuilder Company Information Table 106. VectorBuilder Business Overview Table 107. VectorBuilder Advanced Biopharmaceutical Therapies Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 108. VectorBuilder Advanced Biopharmaceutical Therapies Product Portfolio Table 109. VectorBuilder Recent Development Table 110. Viralgen Company Information Table 111. Viralgen Business Overview Table 112. Viralgen Advanced Biopharmaceutical Therapies Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 113. Viralgen Advanced Biopharmaceutical Therapies Product Portfolio Table 114. Viralgen Recent Development Table 115. ABL Europe Company Information Table 116. ABL Europe Business Overview Table 117. ABL Europe Advanced Biopharmaceutical Therapies Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 118. ABL Europe Advanced Biopharmaceutical Therapies Product Portfolio Table 119. ABL Europe Recent Development Table 120. Research Programs/Design for This Report Table 121. Authors List of This Report Table 122. Secondary Sources Table 123. Primary Sources List of Figures Figure 1. Advanced Biopharmaceutical Therapies Product Image Figure 2. Global Advanced Biopharmaceutical Therapies Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Advanced Biopharmaceutical Therapies Market Size (2021-2032) & (US$ Million) Figure 4. Global Advanced Biopharmaceutical Therapies Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Cell Therapy Services Image Figure 8. Gene Therapy Services Image Figure 9. Nucleic Acid Therapy Services Image Figure 10. Global Advanced Biopharmaceutical Therapies Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Advanced Biopharmaceutical Therapies Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Advanced Biopharmaceutical Therapies Sales Value Share by Type (2021-2032) Figure 13. Biopharmaceutical Industry Image Figure 14. Research and Education Institutions Image Figure 15. Others Image Figure 16. Global Advanced Biopharmaceutical Therapies Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Advanced Biopharmaceutical Therapies Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Advanced Biopharmaceutical Therapies Sales Value Share by Application (2021-2032) Figure 19. Global Advanced Biopharmaceutical Therapies Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Advanced Biopharmaceutical Therapies Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Advanced Biopharmaceutical Therapies Sales Value (2021-2032) & (US$ Million) Figure 22. North America Advanced Biopharmaceutical Therapies Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Advanced Biopharmaceutical Therapies Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Advanced Biopharmaceutical Therapies Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Advanced Biopharmaceutical Therapies Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Advanced Biopharmaceutical Therapies Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Advanced Biopharmaceutical Therapies Sales Value (2021-2032) & (US$ Million) Figure 28. South America Advanced Biopharmaceutical Therapies Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Advanced Biopharmaceutical Therapies Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Advanced Biopharmaceutical Therapies Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Advanced Biopharmaceutical Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Advanced Biopharmaceutical Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Advanced Biopharmaceutical Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Advanced Biopharmaceutical Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Advanced Biopharmaceutical Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Advanced Biopharmaceutical Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Advanced Biopharmaceutical Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Advanced Biopharmaceutical Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Advanced Biopharmaceutical Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Advanced Biopharmaceutical Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Advanced Biopharmaceutical Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Advanced Biopharmaceutical Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Advanced Biopharmaceutical Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Advanced Biopharmaceutical Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Advanced Biopharmaceutical Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Advanced Biopharmaceutical Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Advanced Biopharmaceutical Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Advanced Biopharmaceutical Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Advanced Biopharmaceutical Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Advanced Biopharmaceutical Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Advanced Biopharmaceutical Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Advanced Biopharmaceutical Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Advanced Biopharmaceutical Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Advanced Biopharmaceutical Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Advanced Biopharmaceutical Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Advanced Biopharmaceutical Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Advanced Biopharmaceutical Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Advanced Biopharmaceutical Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Advanced Biopharmaceutical Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Advanced Biopharmaceutical Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Advanced Biopharmaceutical Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Advanced Biopharmaceutical Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Advanced Biopharmaceutical Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Advanced Biopharmaceutical Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Advanced Biopharmaceutical Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Advanced Biopharmaceutical Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Advanced Biopharmaceutical Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Advanced Biopharmaceutical Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Advanced Biopharmaceutical Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Advanced Biopharmaceutical Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Advanced Biopharmaceutical Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Advanced Biopharmaceutical Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Advanced Biopharmaceutical Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Advanced Biopharmaceutical Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Advanced Biopharmaceutical Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Advanced Biopharmaceutical Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Advanced Biopharmaceutical Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Advanced Biopharmaceutical Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Advanced Biopharmaceutical Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Advanced Biopharmaceutical Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Advanced Biopharmaceutical Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Advanced Biopharmaceutical Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Advanced Biopharmaceutical Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Advanced Biopharmaceutical Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Advanced Biopharmaceutical Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Advanced Biopharmaceutical Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Advanced Biopharmaceutical Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Advanced Biopharmaceutical Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Advanced Biopharmaceutical Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Advanced Biopharmaceutical Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Advanced Biopharmaceutical Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Advanced Biopharmaceutical Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Advanced Biopharmaceutical Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Advanced Biopharmaceutical Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Advanced Biopharmaceutical Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Advanced Biopharmaceutical Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Advanced Biopharmaceutical Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Advanced Biopharmaceutical Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Advanced Biopharmaceutical Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Advanced Biopharmaceutical Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Advanced Biopharmaceutical Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Advanced Biopharmaceutical Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Advanced Biopharmaceutical Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Advanced Biopharmaceutical Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Advanced Biopharmaceutical Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Advanced Biopharmaceutical Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Advanced Biopharmaceutical Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Advanced Biopharmaceutical Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Advanced Biopharmaceutical Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Advanced Biopharmaceutical Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Advanced Biopharmaceutical Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Advanced Biopharmaceutical Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Advanced Biopharmaceutical Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Advanced Biopharmaceutical Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Cell Therapy Services
  • Gene Therapy Services
  • Nucleic Acid Therapy Services
Applications
  • Biopharmaceutical Industry
  • Research and Education Institutions
  • Others
Companies covered
  • Lonza
  • Thermo Fisher Scientific
  • Catalent
  • Samsung Biologics
  • AGC Biologics
  • WuXi AppTec
  • Charles River Laboratories
  • Cytiva
  • Rentschler Biopharma
  • Oxford Biomedica
  • OmniaBio
  • Genezen
  • Cellipont Bioservices
  • VectorBuilder
  • Viralgen
  • ABL Europe

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Advanced Biopharmaceutical Therapies Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Advanced Biopharmaceutical Therapies Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Advanced Biopharmaceutical Therapies Market Dynamics
  1. 2.1 Advanced Biopharmaceutical Therapies Industry Trends
  2. 2.2 Advanced Biopharmaceutical Therapies Industry Drivers
  3. 2.3 Advanced Biopharmaceutical Therapies Industry Opportunities and Challenges
  4. 2.4 Advanced Biopharmaceutical Therapies Industry Restraints
3 Advanced Biopharmaceutical Therapies Market by Company
  1. 3.1 Global Advanced Biopharmaceutical Therapies Company Revenue Ranking in 2025
  2. 3.2 Global Advanced Biopharmaceutical Therapies Revenue by Company (2021-2026)
  3. 3.3 Global Advanced Biopharmaceutical Therapies Company Ranking (2024-2026)
  4. 3.4 Global Advanced Biopharmaceutical Therapies Company Manufacturing Base and Headquarters
  5. 3.5 Global Advanced Biopharmaceutical Therapies Company Product Type and Application
  6. 3.6 Global Advanced Biopharmaceutical Therapies Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Advanced Biopharmaceutical Therapies Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Advanced Biopharmaceutical Therapies Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Advanced Biopharmaceutical Therapies Market by Type
  1. 4.1 Advanced Biopharmaceutical Therapies Type Introduction
  2. 4.1.1 Cell Therapy Services
  3. 4.1.2 Gene Therapy Services
  4. 4.1.3 Nucleic Acid Therapy Services
  5. 4.2 Global Advanced Biopharmaceutical Therapies Sales Value by Type
  6. 4.2.1 Global Advanced Biopharmaceutical Therapies Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Advanced Biopharmaceutical Therapies Sales Value by Type (2021-2032)
  8. 4.2.3 Global Advanced Biopharmaceutical Therapies Sales Value Share by Type (2021-2032)
5 Advanced Biopharmaceutical Therapies Market by Application
  1. 5.1 Advanced Biopharmaceutical Therapies Application Introduction
  2. 5.1.1 Biopharmaceutical Industry
  3. 5.1.2 Research and Education Institutions
  4. 5.1.3 Others
  5. 5.2 Global Advanced Biopharmaceutical Therapies Sales Value by Application
  6. 5.2.1 Global Advanced Biopharmaceutical Therapies Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Advanced Biopharmaceutical Therapies Sales Value by Application (2021-2032)
  8. 5.2.3 Global Advanced Biopharmaceutical Therapies Sales Value Share by Application (2021-2032)
6 Advanced Biopharmaceutical Therapies Regional Value Analysis
  1. 6.1 Global Advanced Biopharmaceutical Therapies Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Advanced Biopharmaceutical Therapies Sales Value by Region (2021-2032)
  3. 6.2.1 Global Advanced Biopharmaceutical Therapies Sales Value by Region: 2021-2026
  4. 6.2.2 Global Advanced Biopharmaceutical Therapies Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Advanced Biopharmaceutical Therapies Sales Value (2021-2032)
  7. 6.3.2 North America Advanced Biopharmaceutical Therapies Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Advanced Biopharmaceutical Therapies Sales Value (2021-2032)
  10. 6.4.2 Europe Advanced Biopharmaceutical Therapies Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Advanced Biopharmaceutical Therapies Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Advanced Biopharmaceutical Therapies Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Advanced Biopharmaceutical Therapies Sales Value (2021-2032)
  16. 6.6.2 South America Advanced Biopharmaceutical Therapies Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Advanced Biopharmaceutical Therapies Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Advanced Biopharmaceutical Therapies Sales Value Share by Country, 2025 VS 2032
7 Advanced Biopharmaceutical Therapies Country-level Value Analysis
  1. 7.1 Global Advanced Biopharmaceutical Therapies Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Advanced Biopharmaceutical Therapies Sales Value by Country (2021-2032)
  3. 7.2.1 Global Advanced Biopharmaceutical Therapies Sales Value by Country (2021-2026)
  4. 7.2.2 Global Advanced Biopharmaceutical Therapies Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Advanced Biopharmaceutical Therapies Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Advanced Biopharmaceutical Therapies Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Advanced Biopharmaceutical Therapies Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Advanced Biopharmaceutical Therapies Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Advanced Biopharmaceutical Therapies Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Advanced Biopharmaceutical Therapies Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Advanced Biopharmaceutical Therapies Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Advanced Biopharmaceutical Therapies Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Advanced Biopharmaceutical Therapies Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Advanced Biopharmaceutical Therapies Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Advanced Biopharmaceutical Therapies Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Advanced Biopharmaceutical Therapies Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Advanced Biopharmaceutical Therapies Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Advanced Biopharmaceutical Therapies Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Advanced Biopharmaceutical Therapies Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Advanced Biopharmaceutical Therapies Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Advanced Biopharmaceutical Therapies Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Advanced Biopharmaceutical Therapies Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Advanced Biopharmaceutical Therapies Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Advanced Biopharmaceutical Therapies Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Advanced Biopharmaceutical Therapies Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Advanced Biopharmaceutical Therapies Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Advanced Biopharmaceutical Therapies Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Advanced Biopharmaceutical Therapies Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Advanced Biopharmaceutical Therapies Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Advanced Biopharmaceutical Therapies Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Advanced Biopharmaceutical Therapies Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Advanced Biopharmaceutical Therapies Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Advanced Biopharmaceutical Therapies Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Advanced Biopharmaceutical Therapies Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Advanced Biopharmaceutical Therapies Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Advanced Biopharmaceutical Therapies Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Advanced Biopharmaceutical Therapies Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Advanced Biopharmaceutical Therapies Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Advanced Biopharmaceutical Therapies Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Advanced Biopharmaceutical Therapies Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Advanced Biopharmaceutical Therapies Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Advanced Biopharmaceutical Therapies Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Advanced Biopharmaceutical Therapies Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Advanced Biopharmaceutical Therapies Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Advanced Biopharmaceutical Therapies Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Advanced Biopharmaceutical Therapies Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Advanced Biopharmaceutical Therapies Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Advanced Biopharmaceutical Therapies Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Advanced Biopharmaceutical Therapies Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Advanced Biopharmaceutical Therapies Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Advanced Biopharmaceutical Therapies Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Advanced Biopharmaceutical Therapies Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Advanced Biopharmaceutical Therapies Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Advanced Biopharmaceutical Therapies Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Advanced Biopharmaceutical Therapies Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Advanced Biopharmaceutical Therapies Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Advanced Biopharmaceutical Therapies Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Advanced Biopharmaceutical Therapies Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Advanced Biopharmaceutical Therapies Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Advanced Biopharmaceutical Therapies Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Advanced Biopharmaceutical Therapies Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Advanced Biopharmaceutical Therapies Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Advanced Biopharmaceutical Therapies Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Advanced Biopharmaceutical Therapies Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Advanced Biopharmaceutical Therapies Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Advanced Biopharmaceutical Therapies Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Advanced Biopharmaceutical Therapies Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Advanced Biopharmaceutical Therapies Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Advanced Biopharmaceutical Therapies Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Advanced Biopharmaceutical Therapies Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Advanced Biopharmaceutical Therapies Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Advanced Biopharmaceutical Therapies Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Advanced Biopharmaceutical Therapies Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Advanced Biopharmaceutical Therapies Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Advanced Biopharmaceutical Therapies Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Advanced Biopharmaceutical Therapies Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Advanced Biopharmaceutical Therapies Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Advanced Biopharmaceutical Therapies Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Advanced Biopharmaceutical Therapies Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Advanced Biopharmaceutical Therapies Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Advanced Biopharmaceutical Therapies Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Advanced Biopharmaceutical Therapies Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Advanced Biopharmaceutical Therapies Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Advanced Biopharmaceutical Therapies Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Advanced Biopharmaceutical Therapies Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Advanced Biopharmaceutical Therapies Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Advanced Biopharmaceutical Therapies Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Advanced Biopharmaceutical Therapies Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Lonza
  2. 8.1.1 Lonza Company Information
  3. 8.1.2 Lonza Business Overview
  4. 8.1.3 Lonza Advanced Biopharmaceutical Therapies Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Lonza Advanced Biopharmaceutical Therapies Product Portfolio
  6. 8.1.5 Lonza Recent Developments
  7. 8.2 Thermo Fisher Scientific
  8. 8.2.1 Thermo Fisher Scientific Company Information
  9. 8.2.2 Thermo Fisher Scientific Business Overview
  10. 8.2.3 Thermo Fisher Scientific Advanced Biopharmaceutical Therapies Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Thermo Fisher Scientific Advanced Biopharmaceutical Therapies Product Portfolio
  12. 8.2.5 Thermo Fisher Scientific Recent Developments
  13. 8.3 Catalent
  14. 8.3.1 Catalent Company Information
  15. 8.3.2 Catalent Business Overview
  16. 8.3.3 Catalent Advanced Biopharmaceutical Therapies Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Catalent Advanced Biopharmaceutical Therapies Product Portfolio
  18. 8.3.5 Catalent Recent Developments
  19. 8.4 Samsung Biologics
  20. 8.4.1 Samsung Biologics Company Information
  21. 8.4.2 Samsung Biologics Business Overview
  22. 8.4.3 Samsung Biologics Advanced Biopharmaceutical Therapies Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Samsung Biologics Advanced Biopharmaceutical Therapies Product Portfolio
  24. 8.4.5 Samsung Biologics Recent Developments
  25. 8.5 AGC Biologics
  26. 8.5.1 AGC Biologics Company Information
  27. 8.5.2 AGC Biologics Business Overview
  28. 8.5.3 AGC Biologics Advanced Biopharmaceutical Therapies Revenue and Gross Margin (2021-2026)
  29. 8.5.4 AGC Biologics Advanced Biopharmaceutical Therapies Product Portfolio
  30. 8.5.5 AGC Biologics Recent Developments
  31. 8.6 WuXi AppTec
  32. 8.6.1 WuXi AppTec Company Information
  33. 8.6.2 WuXi AppTec Business Overview
  34. 8.6.3 WuXi AppTec Advanced Biopharmaceutical Therapies Revenue and Gross Margin (2021-2026)
  35. 8.6.4 WuXi AppTec Advanced Biopharmaceutical Therapies Product Portfolio
  36. 8.6.5 WuXi AppTec Recent Developments
  37. 8.7 Charles River Laboratories
  38. 8.7.1 Charles River Laboratories Company Information
  39. 8.7.2 Charles River Laboratories Business Overview
  40. 8.7.3 Charles River Laboratories Advanced Biopharmaceutical Therapies Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Charles River Laboratories Advanced Biopharmaceutical Therapies Product Portfolio
  42. 8.7.5 Charles River Laboratories Recent Developments
  43. 8.8 Cytiva
  44. 8.8.1 Cytiva Company Information
  45. 8.8.2 Cytiva Business Overview
  46. 8.8.3 Cytiva Advanced Biopharmaceutical Therapies Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Cytiva Advanced Biopharmaceutical Therapies Product Portfolio
  48. 8.8.5 Cytiva Recent Developments
  49. 8.9 Rentschler Biopharma
  50. 8.9.1 Rentschler Biopharma Company Information
  51. 8.9.2 Rentschler Biopharma Business Overview
  52. 8.9.3 Rentschler Biopharma Advanced Biopharmaceutical Therapies Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Rentschler Biopharma Advanced Biopharmaceutical Therapies Product Portfolio
  54. 8.9.5 Rentschler Biopharma Recent Developments
  55. 8.10 Oxford Biomedica
  56. 8.10.1 Oxford Biomedica Company Information
  57. 8.10.2 Oxford Biomedica Business Overview
  58. 8.10.3 Oxford Biomedica Advanced Biopharmaceutical Therapies Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Oxford Biomedica Advanced Biopharmaceutical Therapies Product Portfolio
  60. 8.10.5 Oxford Biomedica Recent Developments
  61. 8.11 OmniaBio
  62. 8.11.1 OmniaBio Company Information
  63. 8.11.2 OmniaBio Business Overview
  64. 8.11.3 OmniaBio Advanced Biopharmaceutical Therapies Revenue and Gross Margin (2021-2026)
  65. 8.11.4 OmniaBio Advanced Biopharmaceutical Therapies Product Portfolio
  66. 8.11.5 OmniaBio Recent Developments
  67. 8.12 Genezen
  68. 8.12.1 Genezen Company Information
  69. 8.12.2 Genezen Business Overview
  70. 8.12.3 Genezen Advanced Biopharmaceutical Therapies Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Genezen Advanced Biopharmaceutical Therapies Product Portfolio
  72. 8.12.5 Genezen Recent Developments
  73. 8.13 Cellipont Bioservices
  74. 8.13.1 Cellipont Bioservices Company Information
  75. 8.13.2 Cellipont Bioservices Business Overview
  76. 8.13.3 Cellipont Bioservices Advanced Biopharmaceutical Therapies Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Cellipont Bioservices Advanced Biopharmaceutical Therapies Product Portfolio
  78. 8.13.5 Cellipont Bioservices Recent Developments
  79. 8.14 VectorBuilder
  80. 8.14.1 VectorBuilder Company Information
  81. 8.14.2 VectorBuilder Business Overview
  82. 8.14.3 VectorBuilder Advanced Biopharmaceutical Therapies Revenue and Gross Margin (2021-2026)
  83. 8.14.4 VectorBuilder Advanced Biopharmaceutical Therapies Product Portfolio
  84. 8.14.5 VectorBuilder Recent Developments
  85. 8.15 Viralgen
  86. 8.15.1 Viralgen Company Information
  87. 8.15.2 Viralgen Business Overview
  88. 8.15.3 Viralgen Advanced Biopharmaceutical Therapies Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Viralgen Advanced Biopharmaceutical Therapies Product Portfolio
  90. 8.15.5 Viralgen Recent Developments
  91. 8.16 ABL Europe
  92. 8.16.1 ABL Europe Company Information
  93. 8.16.2 ABL Europe Business Overview
  94. 8.16.3 ABL Europe Advanced Biopharmaceutical Therapies Revenue and Gross Margin (2021-2026)
  95. 8.16.4 ABL Europe Advanced Biopharmaceutical Therapies Product Portfolio
  96. 8.16.5 ABL Europe Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst